DBH‐AS1 is upregulated by METTL3‐mediated m6A modification, and overexpression of DBH‐AS1 sponges miR‐3163 and upregulates the expression of USP44, a target gene of miR‐3163, thereby reducing gemcitabine resistance and suppressing cancer growth [21]. The gene discussed is METTL3; the disease is cancer.